"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
| Descriptor ID |
D003561
|
| MeSH Number(s) |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
|
| Concept/Terms |
Cytarabine- Cytarabine
- Arabinofuranosylcytosine
- Aracytidine
- Cytosine Arabinoside
- Arabinoside, Cytosine
- Arabinosylcytosine
Cytosar- Cytosar
- Cytosar-U
- Cytosar U
- CytosarU
|
Below are MeSH descriptors whose meaning is more general than "Cytarabine".
Below are MeSH descriptors whose meaning is more specific than "Cytarabine".
This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2005 | 1 | 3 | 4 |
| 2007 | 0 | 2 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytarabine" by people in Profiles.
-
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021 07 13; 5(13):2775-2787.
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
-
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leuk Lymphoma. 2020 03; 61(3):631-640.
-
Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation. World Neurosurg. 2019 Aug; 128:381-384.
-
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. Cancer Chemother Pharmacol. 2019 07; 84(1):163-173.
-
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692.
-
Phase 3 results for vosaroxin/cytarabine in the subset of patients =60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 11; 103(11):e514-e518.
-
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036.
-
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
-
Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015 Apr; 122(2):391-8.